- Active not recruitingPHASE3
Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
This study is testing a new medicine, atogepant, to see if it can help prevent menstrual migraines. Researchers will see how well it works and if it has any side effects, compared to a dummy pill.
For: Menstrual Migraine (MM)China · Czechia · Germany - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multicenter, Open-Label 156-Week Extension Study To Evaluate The Long-Term Safety And Tolerability Of Oral Atogepant For The Prevention Of Migraine In Participants With Chronic Or Episodic Migraine
This study looks at the long-term safety of a new medicine called atogepant for preventing migraine headaches. It's for people who get migraines often, either regularly or sometimes, and they will take the medicine for up to three years to see how well they tolerate it.
For: Chronic or Episodic Migraine (Migraine without aura, migraine with aura, or chronic migraine)Spain · Denmark · Germany - Active not recruitingPHASE3
Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine
This study compares two medicines, atogepant and topiramate, for preventing migraine headaches. Researchers want to see which medicine causes fewer side effects in adults with migraines. It involves taking pills and having regular check-ups over a long period.
For: MigraineAustria · Belgium · Canada - RecruitingPHASE3
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
This study is testing a new tablet called atogepant to see if it can help prevent chronic migraines in young people aged 12 to 17. We want to know if it's safe and if it works better than a dummy pill.
For: Chronic MigraineUnited States · Canada · Denmark - RecruitingPHASE3
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
This study looks at a medicine called atogepant for children and teenagers aged 6 to 17 who get occasional migraines. It will check if the medicine is safe and if it helps reduce migraines, as there aren't many approved treatments for young people.
For: Episodic MigraineUnited States · Belgium · Canada - Enrolling by invitationPHASE3
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine
This study looks at the long-term safety of a medicine called atogepant for children and teenagers (6-17 years old) who get migraines. Atogepant is already approved for adults and helps prevent migraines. This study wants to see how well it works and if it's safe for younger people over a longer time.
For: Migraine ProphylaxisUnited States · Belgium · Canada - Active not recruitingPHASE3
Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine
This study is testing a tablet called atogepant for treating migraine attacks. It aims to see if it's safe and effective at stopping migraines quickly. Atogepant is already approved for preventing migraines. Around 1300 adults aged 18-75 will take part worldwide.
For: MigraineBelgium · China · Czechia